Cost‐effectiveness of universal esophageal cancer screening for newly diagnosed oral cancer patients.

Background and Aim Methods Results Conclusions Oral and esophageal cancers are globally prevalent, especially in East Asia. Over half of head and neck cancer patients developing second primary esophageal cancer (SPEC) were initially diagnosed with oral cavity cancer (OCC). This study assessed the cost‐effectiveness of universal endoscopic screening for early SPEC prevention in newly diagnosed OCC patients at different stages.This study employed Markov cohort models to evaluate the cost‐effectiveness of endoscopic SPEC screening post‐OCC diagnosis (stages 0 to IV) between screened and non‐screened groups. Four surveillance frequencies were assessed: (i) one time, (ii) annual for 3 years, (iii) annual for 10 years, and (iv) annual for life. A hypothetical cohort of 100 000 cases across stages was compared for costs and quality‐adjusted life‐years (QALYs), discounted annually at 3%.All four screening strategies were beneficial for all OCC stages, especially for early‐stage patients, resulting in higher QALYs. Lifetime/annual screening from the payer's perspective proved most favorable, with incremental QALYs of 1.23 at stage 0 and 0.06 at stage IV. Incremental costs for this strategy ranged from NTD 121 331 (USD 4044) at stage 0 to NTD 13 032 (USD 434) at stage IV. Both incremental costs and incremental cost‐effectiveness ratio (ICER) values indicated cost savings from a societal perspective. The ICER values ranged from NTD −626 440 (USD −20 881) at stage 0 and NTD −475 021 (USD −15 834) at stage IV.Overall, our study provided cost‐effectiveness evidences to understanding the cost‐effectiveness of endoscopic screening in OCC patients, particularly emphasizing the benefits of early and consistent screening. [ABSTRACT FROM AUTHOR]